Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7192938 | HOFFMANN LA ROCHE | Method of treatment using bisphosphonic acid |
May, 2023
(2 months from now) | |
US7718634 | HOFFMANN LA ROCHE | Method of treatment using bisphosphonic acid |
May, 2023
(2 months from now) | |
US7410957 | HOFFMANN LA ROCHE | Method of treatment using bisphosphonic acid |
May, 2023
(2 months from now) |
Drugs and Companies using IBANDRONATE SODIUM ingredient
Market Authorisation Date: 16 May, 2003
Treatment: Treatment and prevention of osteoporosis in postmenopausal women by once-monthly oral administration of ibandronate sodium monohydrate equivalent to 150mg of ibandronic acid; Treatment and prevention of osteoporosis
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9642911 | HOFFMANN LA ROCHE | Pharmaceutical dosage forms comprising valganciclovir hydrochloride |
Dec, 2027
(4 years from now) | |
US8889109 | HOFFMANN LA ROCHE | Pharmaceutical dosage forms comprising valganciclovir hydrochloride |
Dec, 2027
(4 years from now) |
Drugs and Companies using VALGANCICLOVIR HYDROCHLORIDE ingredient
Market Authorisation Date: 28 August, 2009
Treatment: NA
Dosage: FOR SOLUTION;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8143271 | HOFFMANN LA ROCHE | NA |
Jun, 2026
(3 years from now) | |
US7504509 | HOFFMANN LA ROCHE | Compounds and methods for development of Ret modulators |
Oct, 2026
(3 years from now) | |
US7863288 | HOFFMANN LA ROCHE | NA |
Jun, 2029
(6 years from now) | |
US8741920 | HOFFMANN LA ROCHE | Process for the manufacture of pharmaceutically active compounds |
Jul, 2030
(7 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8470818 | HOFFMANN LA ROCHE | NA |
Aug, 2026
(3 years from now) | |
US9447089 | HOFFMANN LA ROCHE | Compositions and uses thereof |
Jun, 2032
(9 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Nov 6, 2024 |
Drugs and Companies using VEMURAFENIB ingredient
Market Authorisation Date: 17 August, 2011
Treatment: Zelboraf is indicated for the treatment of patients with erdheim-chester disease with braf v600 mutation; Treatment of patients with unresectable or metastatic melanoma with brafv600e mutation as detected by an fda approved test
Dosage: TABLET;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic